TY  - GEN
AU  - Picozzi,Vincent J
AU  - Ramanathan,Ramesh K
AU  - Lowery,Maeve A
AU  - Ocean,Allyson J
AU  - Mitchel,Edith P
AU  - O'Neil,Bert H
AU  - Guarino,Michael J
AU  - Conkling,Paul R
AU  - Cohen,Steven J
AU  - Bahary,Nathan
AU  - Frank,Richard C
AU  - Dragovich,Tomislav
AU  - Bridges,Benjamin B
AU  - Braiteh,Fadi S
AU  - Starodub,Alexander N
AU  - Lee,Fa-Chyi
AU  - Gribbin,Thomas E
AU  - Richards,Donald A
AU  - Lee,Marie
AU  - Korn,Ronald L
AU  - Pandit-Taskar,Neeta
AU  - Goldsmith,Stanley J
AU  - Intenzo,Charles M
AU  - Sheikh,Arif
AU  - Manzone,Timothy C
AU  - Horne,Heather
AU  - Sharkey,Robert M
AU  - Wegener,William A
AU  - O'Reilly,Eileen M
AU  - Goldenberg,David M
AU  - Von Hoff,Daniel D
TI  - (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies
SN  - 1879-0852
PY  - 2015///1109
KW  - Adenocarcinoma
KW  - immunology
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - adverse effects
KW  - Antimetabolites, Antineoplastic
KW  - administration & dosage
KW  - Chemotherapy, Adjuvant
KW  - Deoxycytidine
KW  - Disease Progression
KW  - Feasibility Studies
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Mucins
KW  - Pancreatic Neoplasms
KW  - Radioimmunotherapy
KW  - Radiopharmaceuticals
KW  - Remission Induction
KW  - Thrombocytopenia
KW  - chemically induced
KW  - Time Factors
KW  - Treatment Outcome
KW  - United States
KW  - Yttrium Radioisotopes
KW  - Gemcitabine
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.ejca.2015.06.119
ER  -